Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. / Chang, Joan; Lucas, Morghan C; Leonte, Lidia Elena; Garcia-Montolio, Marc; Singh, Lukram Babloo; Findlay, Alison D; Deodhar, Mandar; Foot, Jonathan S; Jarolimek, Wolfgang; Timpson, Paul; Erler, Janine Terra; Cox, Thomas Robert.

In: OncoTarget, Vol. 8, No. 16, 10.02.2017, p. 26066-26078.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Chang, J, Lucas, MC, Leonte, LE, Garcia-Montolio, M, Singh, LB, Findlay, AD, Deodhar, M, Foot, JS, Jarolimek, W, Timpson, P, Erler, JT & Cox, TR 2017, 'Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer', OncoTarget, vol. 8, no. 16, pp. 26066-26078. https://doi.org/10.18632/oncotarget.15257

APA

Chang, J., Lucas, M. C., Leonte, L. E., Garcia-Montolio, M., Singh, L. B., Findlay, A. D., Deodhar, M., Foot, J. S., Jarolimek, W., Timpson, P., Erler, J. T., & Cox, T. R. (2017). Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. OncoTarget, 8(16), 26066-26078. https://doi.org/10.18632/oncotarget.15257

Vancouver

Chang J, Lucas MC, Leonte LE, Garcia-Montolio M, Singh LB, Findlay AD et al. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. OncoTarget. 2017 Feb 10;8(16):26066-26078. https://doi.org/10.18632/oncotarget.15257

Author

Chang, Joan ; Lucas, Morghan C ; Leonte, Lidia Elena ; Garcia-Montolio, Marc ; Singh, Lukram Babloo ; Findlay, Alison D ; Deodhar, Mandar ; Foot, Jonathan S ; Jarolimek, Wolfgang ; Timpson, Paul ; Erler, Janine Terra ; Cox, Thomas Robert. / Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. In: OncoTarget. 2017 ; Vol. 8, No. 16. pp. 26066-26078.

Bibtex

@article{6e655390560c4760b49c227c79753d56,
title = "Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer",
abstract = "Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors. Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer. We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer. Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis. Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver. Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.",
author = "Joan Chang and Lucas, {Morghan C} and Leonte, {Lidia Elena} and Marc Garcia-Montolio and Singh, {Lukram Babloo} and Findlay, {Alison D} and Mandar Deodhar and Foot, {Jonathan S} and Wolfgang Jarolimek and Paul Timpson and Erler, {Janine Terra} and Cox, {Thomas Robert}",
year = "2017",
month = feb,
day = "10",
doi = "10.18632/oncotarget.15257",
language = "English",
volume = "8",
pages = "26066--26078",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "16",

}

RIS

TY - JOUR

T1 - Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer

AU - Chang, Joan

AU - Lucas, Morghan C

AU - Leonte, Lidia Elena

AU - Garcia-Montolio, Marc

AU - Singh, Lukram Babloo

AU - Findlay, Alison D

AU - Deodhar, Mandar

AU - Foot, Jonathan S

AU - Jarolimek, Wolfgang

AU - Timpson, Paul

AU - Erler, Janine Terra

AU - Cox, Thomas Robert

PY - 2017/2/10

Y1 - 2017/2/10

N2 - Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors. Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer. We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer. Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis. Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver. Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.

AB - Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors. Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer. We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer. Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis. Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver. Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.

U2 - 10.18632/oncotarget.15257

DO - 10.18632/oncotarget.15257

M3 - Journal article

C2 - 28199967

VL - 8

SP - 26066

EP - 26078

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -

ID: 174632765